Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92


The theta-defensin, retrocyclin, inhibits HIV-1 entry.

M√ľnk C, Wei G, Yang OO, Waring AJ, Wang W, Hong T, Lehrer RI, Landau NR, Cole AM.

AIDS Res Hum Retroviruses. 2003 Oct;19(10):875-81.


RC-101, a retrocyclin-1 analogue with enhanced activity against primary HIV type 1 isolates.

Owen SM, Rudolph DL, Wang W, Cole AM, Waring AJ, Lal RB, Lehrer RI.

AIDS Res Hum Retroviruses. 2004 Nov;20(11):1157-65.


Retrocyclin, an antiretroviral theta-defensin, is a lectin.

Wang W, Cole AM, Hong T, Waring AJ, Lehrer RI.

J Immunol. 2003 May 1;170(9):4708-16.


Theta-defensins prevent HIV-1 Env-mediated fusion by binding gp41 and blocking 6-helix bundle formation.

Gallo SA, Wang W, Rawat SS, Jung G, Waring AJ, Cole AM, Lu H, Yan X, Daly NL, Craik DJ, Jiang S, Lehrer RI, Blumenthal R.

J Biol Chem. 2006 Jul 7;281(27):18787-92. Epub 2006 Apr 28.


A theta-defensin composed exclusively of D-amino acids is active against HIV-1.

Owen SM, Rudolph D, Wang W, Cole AM, Sherman MA, Waring AJ, Lehrer RI, Lal RB.

J Pept Res. 2004 Jun;63(6):469-76.


Theta defensins protect cells from infection by herpes simplex virus by inhibiting viral adhesion and entry.

Yasin B, Wang W, Pang M, Cheshenko N, Hong T, Waring AJ, Herold BC, Wagar EA, Lehrer RI.

J Virol. 2004 May;78(10):5147-56.


Retrocyclin-2: structural analysis of a potent anti-HIV theta-defensin.

Daly NL, Chen YK, Rosengren KJ, Marx UC, Phillips ML, Waring AJ, Wang W, Lehrer RI, Craik DJ.

Biochemistry. 2007 Sep 4;46(35):9920-8. Epub 2007 Aug 8.


HIV-1 adapts to a retrocyclin with cationic amino acid substitutions that reduce fusion efficiency of gp41.

Cole AL, Yang OO, Warren AD, Waring AJ, Lehrer RI, Cole AM.

J Immunol. 2006 Jun 1;176(11):6900-5.


The B-oligomer of pertussis toxin deactivates CC chemokine receptor 5 and blocks entry of M-tropic HIV-1 strains.

Alfano M, Schmidtmayerova H, Amella CA, Pushkarsky T, Bukrinsky M.

J Exp Med. 1999 Sep 6;190(5):597-605.


Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4.

Zhao Q, Ma L, Jiang S, Lu H, Liu S, He Y, Strick N, Neamati N, Debnath AK.

Virology. 2005 Sep 1;339(2):213-25.


Inhibitory effects of small-molecule CCR5 antagonists on human immunodeficiency virus type 1 envelope-mediated membrane fusion and viral replication.

Takashima K, Miyake H, Furuta RA, Fujisawa JI, Iizawa Y, Kanzaki N, Shiraishi M, Okonogi K, Baba M.

Antimicrob Agents Chemother. 2001 Dec;45(12):3538-43.


Peptides from second extracellular loop of C-C chemokine receptor type 5 (CCR5) inhibit diverse strains of HIV-1.

Dogo-Isonagie C, Lam S, Gustchina E, Acharya P, Yang Y, Shahzad-ul-Hussan S, Clore GM, Kwong PD, Bewley CA.

J Biol Chem. 2012 Apr 27;287(18):15076-86. doi: 10.1074/jbc.M111.332361. Epub 2012 Mar 8.


The bis-azo compound FP-21399 inhibits HIV-1 replication by preventing viral entry.

Zhang JL, Choe H, Dezube BJ, Farzan M, Sharma PL, Zhou XC, Chen LB, Ono M, Gillies S, Wu Y, Sodroski JG, Crumpacker CS.

Virology. 1998 May 10;244(2):530-41.


Inhibition of dual/mixed tropic HIV-1 isolates by CCR5-inhibitors in primary lymphocytes and macrophages.

Surdo M, Balestra E, Saccomandi P, Di Santo F, Montano M, Di Carlo D, Sarmati L, Aquaro S, Andreoni M, Svicher V, Perno CF, Ceccherini-Silberstein F.

PLoS One. 2013 Jul 9;8(7):e68076. doi: 10.1371/journal.pone.0068076. Print 2013.


A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5.

Dragic T, Trkola A, Thompson DA, Cormier EG, Kajumo FA, Maxwell E, Lin SW, Ying W, Smith SO, Sakmar TP, Moore JP.

Proc Natl Acad Sci U S A. 2000 May 9;97(10):5639-44.


theta-Defensin pseudogenes in HIV-1-exposed, persistently seronegative female sex-workers from Thailand.

Yang C, Boone L, Nguyen TX, Rudolph D, Limpakarnjanarat K, Mastro TD, Tappero J, Cole AM, Lal RB.

Infect Genet Evol. 2005 Jan;5(1):11-5.


Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist.

Takashima K, Miyake H, Kanzaki N, Tagawa Y, Wang X, Sugihara Y, Iizawa Y, Baba M.

Antimicrob Agents Chemother. 2005 Aug;49(8):3474-82.


Activity of alpha- and theta-defensins against primary isolates of HIV-1.

Wang W, Owen SM, Rudolph DL, Cole AM, Hong T, Waring AJ, Lal RB, Lehrer RI.

J Immunol. 2004 Jul 1;173(1):515-20.


HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro.

Svicher V, Balestra E, Cento V, Sarmati L, Dori L, Vandenbroucke I, D'Arrigo R, Buonomini AR, Van Marck H, Surdo M, Saccomandi P, Mostmans W, Aerssens J, Aquaro S, Stuyver LJ, Andreoni M, Ceccherini-Silberstein F, Perno CF.

Antiviral Res. 2011 Apr;90(1):42-53. doi: 10.1016/j.antiviral.2011.02.005. Epub 2011 Feb 22.


Supplemental Content

Support Center